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1. Executive Summary 
The PhenoMeNal project does not generate Metabolomics data. In order to create 
the projected data processing pipeline and for testing our ethical, legal and social 
implications (ELSI) goals, however, we need to use data sets that closely mimic the 
types of data which will be analysed by our future users. These test data sets (and 
data used by future beneficiaries of PhenoMeNal) should therefore satisfy ELSI 
requirements. Before using any already existing datasets, we have evaluated the 
associated documentation for each dataset. In particular, where data is not open and 
freely available, we have obtained ethical approval documentation, patient 
information and patient permission forms and these documents are collated in the 
Appendix. This information provides a firm basis on how to decide on the use cases 
for each of the datasets available. For example, based on the available ELSI 
information, some data will only be used at the host institution, where ethical 
approval for use at that institution is present. Open data (such as MetaboLights data, 
http://www.ebi.ac.uk/metabolights/) can be freely used within the terms of use of the 
EMBL-EBI within the consortium. The datasets described here are also reported in 
D9.1 (Report on existing software tools, workflows and analytical pipelines initially 
supported in the PhenoMeNal grid, submitted M6). 
2. Project Objectives 
 







Develop appropriate policies, procedures and management 
accountability and structures to provide a robust 
governance framework for information management. 
Raise awareness of information governance within the 
consortium and assure on going compliance. 
Ensure that ethical standards and guidelines of 
Horizon2020 will be rigorously applied, regardless of the 









3. Detailed report on the deliverable 
3.1. Background 
PhenoMeNal will create a software environment that can process diverse ‘omics 
data sets with a focus specifically on human metabolomics data. The PhenoMeNal 
project does not generate Metabolomics data, but in order to properly develop the 
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software environment, a number of standard datasets will be required to test the 
formats, data processing pipelines, user interaction and the stability of the software 
and to make sure that our procedures are in line with generally accepted ELSI 
guidelines. For this reason, we have selected a number of use cases that typically 
reflect the type of data that will be used in PhenoMeNal. 
To begin testing software in Phenomenal, we will initially use publically available 
anonymised data as this will enable timely testing of the software without the much 
higher level security constraints required for confidential patient data, which will 
nevertheless be dealt with later in the project. In D7.3, Evaluation report for the 
introduction of a data provider form, we have outlined our approach to data 
exchange in PhenoMenal, and how a data provider form will be used to allow 
movement of data between groups with approval within ELSI constraints. The use of 
this approach will be evaluated for the use of any datasets that are not open. It 
should be stressed that data will only be used with permission of the data provider, 
and we are relying on the provider to give guidance that they have obtained informed 
patient permission for use in Phenomenal. 
It is to be noted that even the use of such publically available data is associated with 
ethical and legal guidelines. These datasets are listed below along with their ELSI 
status. For each dataset we have listed the ethical permissions, patient information 
forms and patient permission forms. For publically available data from the EBI 
MetaboLights database, we refer the reader to the EBI terms of use 
(http://www.ebi.ac.uk/about/terms-of-use). 
This deliverable refers to Task 7.7: Identify human clinical datasets to test drive 
development and ensure that the ethical approvals cover use within the PhenoMeNal 
project, including the non-EC partner Swiss Institute of Bioinformatics (SIB). Provide 
EC/REA with copies of ethical approvals and related informed consent forms and 
information materials for patients. 
3.2. Current PhenoMeNal data sets 
Here we describe the current status of ethical permissions and documentation for the 
five use case data sets already presented in D9.1. The studies chosen, availability of 
suitable data and the available ELSI information on these studies is as varied as the 
status (open or restricted data) and the trans-national sources of the data. As 
PhenoMeNal matures, datasets will be added or removed depending on their 
suitability for testing the platform as well as the ELSI information available for the 
data.  
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Use Case 1: Analysis of the MESA research study on subclinical 
cardiovascular diseases. 
The Multi-Ethnic Study of Atherosclerosis (MESA, http://www.mesa-nhlbi.org/) is a 
medical research study involving more than 6,000 men and women in the United 
States. The study focuses on the characteristics of subclinical cardiovascular 
diseases. As part of the COMBI-BIO project (Development of combinational 
biomarkers for subclinical atherosclerosis, http://www.combi-bio.eu/), metabolomics 
data was produced in two phases for 4,000 MESA participants from serum samples 
using NMR and LC-MS platforms. The data in this cohort: 
a) Will be publically available once deposited in dbGAP (database of genotypes and 
phenotypes, http://www.ncbi.nlm.nih.gov/gap, expected by July 2016). 
b) We currently have permission to distribute and use the data. An email from the 
Governance committee is attached. 
Open-access data can be browsed online or downloaded from dbGaP without prior 
permission or authorization. For more sensitive data sets involving personal health 
information the download of data is allowed after registration with the site. Since the 
data used in PhenoMeNal will be publically available from dbGap, we will follow the 
Open Access protocols at: 
a) http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/about.html  
The study is described at: 
b) https://www.mesa-nhlbi.org/aboutMESAOverviewProtocol.aspx#protocol 
 
For use of the MESA data, we specifically requested a response from the access 
committee and this is attached in the Annex 6.1  (email from the coordinating 
committee giving permission for use for MESA data in PhenoMeNal). 
The initial use of MESA data will be as an example data set to test the tools that are 
currently being developed. We are using a subset, the COMBI-BIO MESA data as 
this use-case. This data follows quite closely the workflow now being used in the 
National Phenome Centre and we know the data well. The purpose would be for 
development and testing of software/computational tools: no biological analysis will 
be done or published. 
 
Use Case 2: Analysis of the CoLaus population-based study on cardiovascular 
diseases and risk factors 
The main goals of this study are to obtain information on the epidemiology and 
genetic determinants of cardiovascular risk factors and diseases as well as mental 
health in the adult population of Lausanne. This data will be solely for use within 
PhenoMeNal as this is not a public (open) data. We are in communication with the 
study PI and have received ethical documentation from them. The use of the data 
will be behind secure firewalls and used for testing purposes of the software 
  6 
processing and analysis. We do not expect to publish any biological findings. Ethical 
approval and patient information and consent forms are attached in Appendix 6.2. 
 
Use Case 3: Data processing for the Uppsala Fibromyalgia study 
The patient samples were collected in Norway. The original ethical approval is 
included in the appendix. The controls have been donated from patients in Rumania. 
Their consent form information in Rumanian is attached in Annex 6.3. This data will 
be solely for use within Phenomenal as this is not public (open) data. We are in 
communication with the study PI and have received ethical documentation from 
them. The use of the data will be behind secure firewalls and used for testing 
purposes of the software processing and analysis. We do not expect to publish any 
biological findings. 
 
Use Case 4: Data processing, statistical analysis, and annotation of the 
“Physiological Variations of the Urine Metabolome” 
This study is already publically available in the MetaboLights repository at the EBI 
with accession number MTBLS20 (http://www.ebi.ac.uk/metabolights/MTBLS20). 
The complete statistical processing workflow is available in Workflow4Metabolomics 
(http://workflow4metabolomics.org) under reference W4M00001 
(http://workflow4metabolomics.org/dataset_sacurine). Since this is an open data 
publicly available, de-anonymised and filtered, this data does not include consent 
forms, ethical approval or patient information at this source. The terms of use can be 
visited at: http://www.ebi.ac.uk/about/terms-of-use  
 
Use Case 5: Data processing for fluxomic analyses. 
This study is deposited in the MetaboLights repository at the EBI and will become 
publically available during the PhenoMeNal project (data may be deposited with a 
future release data to allow first publication of results etc. by the depositors). Since 
this will be open data, publicly available de-anonymised and filtered open access 
data does not include consent forms, ethical approval or patient information at this 
source. The terms of use are at this web address: http://www.ebi.ac.uk/about/terms-
of-use. 
4. Delivery and Schedule 
The deliverable is delayed:  No 
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5. Background information  
Patient and research subject data is very sensitive, and it is paramount to 
establish a robust governance framework for overall information management 
including sensitive data. The PhenoMeNal e-infrastructure will be able to cope with 
data generated from comprehensive clinical, genotypic, ‘omics and analytic 
sources including medical records, electronic health records, clinical 
measurements, genotypic data, phenotypic data from tissue and biofluid analysis, 
image and pathology data. Primarily, all data collected and held within the project 
will comply with all local laws, regulations and ethics. All personal information will 
be processed in accordance with accepted Data  
Protection Principles outlined above. Responsibility for data will be with the host  
Institution/data provider.  
 
The use of patient research data in Phenomenal as a test bed for the 
implementation of software and algorithms was determined by the availability of 
the data, its usefulness in representing probable data sets and also any 
restrictions on use within an ELSI environment. Some of the data is open, and can 
be freely downloaded and used while other data has restrictions applied to it (such 
as only being permissible to use the data within the Phenomenal project at a 
particular site). We have obtained ethical approval documents, patient information 
data and patient permission forms and discussed with the data providers (PI’s) 
how we will use the data and obtained permission. This approach allows us to 
decide whether we are using the data in a way that conforms to the ELSI of the 
study. 
 
This deliverable refers to Task 7.7: Identify human clinical datasets to test drive 
development and ensure that the ethical approvals cover use within the 
PhenoMeNal project, including the non-EC partner Swiss Institute of 
Bioinformatics (SIB). Provide EC/REA with copies of ethical approvals and related 
informed consent forms and information materials for patients. 




IPB UB UL UOXF SIB UU 
1.5  0.2   0.4   
6. Annexes 
6.1 MESA study – ethical information, patient information and forms 
 
a) Email confirming PhenoMeNal use of MESA data. 
 
From: Craig Johnson [mailto:wcraigj@u.washington.edu]  
Sent: Monday, February 29, 2016 10:03 PM 
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To: David Herrington; 'David Vu'; 'Philip Greenland'; 'Ebbels, Timothy M D' 
Cc: 'Kayleen Williams'; 'Glen, Robert C'; 'Pearce, Jake T M'; Gregory L. Burke; 
'Russell P Tracy'; 'Jerome I. Rotter' 




MESA Steering Committee has considered and approved this use.  The MESA 
DMDA already executed with Imperial College is still considered binding and will 
suffice for this additional use as well. 
 
When Steering Committee discussed, it was noted that the version of the data 
available at Coordinating Center (with MESA IDs as was used for COMBI-Bio) could 
also be used if more convenient.  David Vu made progress in applying corrections to 
IDs in the metabolomic data files today and expects to make additional progress with 
the conversion to SHARe ID in the next day or two, so we can provide access to 







Project Director, MESA Coordinating Center University of Washington 
Collaborative Health Studies Coordinating Center Building 29, Suite 310 
6200 NE 74th Street 







b) Mesa Ethical Approval: Approval of Continuing Review 
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c) MESA Informed Consent description
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6.2 CoLaus study - ethical permission, patient information and forms 
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b) Consent Forms 
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c) Patient Information 
 
Formulaire d’information pour les participants 
1. Raisons et objectifs de l’étude 
Les maladies cardiovasculaires comme l’infarctus du myocarde, les attaques 
cérébrales font partie des maladies les plus courantes de notre société et sont une 
cause important de mortalité. De nombreux facteurs peuvent augmenter le risque de 
développer des maladies cardiovasculaires, dont une tension artérielle élevée 
(l’hypertension), le tabac, le diabète, l’obésité, une histoire familiale de maladies 
cardiovasculaires et le manqué d’exercice. Alors que certains de ces facteurs de 
risque dépendent du style de vie (tabac, exercice, nutrition) d’autres ont une 
composante génétique importante (hypertension, diabète). Afin de mieux 
comprendre l’influence des facteurs de risque et de découvrir de nouveaux gènes 
impliqués dans les maladies cardiovasculaires, il est nécessaire d’étudier des 
populations de grande taille et homogènes. Les objectifs de cette étude sont : 
a) De faire une enquête sur les facteurs de risque cardiovasculaires au sens large 
d’une 
population homogène telle que Lausanne, 
b) D’étudier le matériel génétique (l’ADN) et les marqueurs (protéines et lipides, 
comme 
le cholestérol) associés aux facteurs de risque cardiovasculaires au sens large et 
aux 
maladies associées tels que l’hypertension, le diabète, l’obésité et des troubles de 
l’humeur. 
Nous espérons recruter 6000 participants à Lausanne. 
L’étude sera menée par des chercheurs du Centre Hospitalier Universitaire Vaudois 
(CHUV) et de l’Université de Lausanne en association avec GlaxoSmithKline (GSK). 
2. Que devrais-je faire si j’accepte de prendre part à cette étude ? 
Si vous acceptez de participer à cette étude, nous vous ferons remplir un 
questionnaire sur vos antécédents médicaux, les antécédents médicaux de votre 
famille, votre état de santé actuel ainsi que vos traitements en cours et votre origine 
ethnique. Nous mesurerons votre poids, votre taille, et votre tension artérielle. Nous 
vous demanderons de donner un échantillon de 50 ml de sang à jeun, ainsi qu’un 
échantillon d’urine de 10 ml. Le materiel génétique (ADN) sera extrait de votre sang 
et les marqueurs seront mesurés dans votre sang et votre urine. Finalement, nous 
vous demanderons si vous acceptez que nous prenions contact avec vous à l’avenir 
pour répondre à certaines questions sur votre santé et votre tension artérielle. 
3. Quels sont les risques? 
Les risques physiques et l’inconfort associés à la prise de sang sont les mêmes que 
pour n’importe quel prélèvement de sang et peuvent comprendre un hématome ou 
une inflammation locale. 
2 
4. Quels sont les avantages pour moi ? 
Nous mesurerons votre tension artérielle, votre taux de cholestérol, de triglycérides 
et de glucose (sucre) dans le sang et le médecin responsable de l’étude vous 
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communiquera les résultats de ces analyses. Il n’y aura aucun avantage direct 
immédiat pour vous si vous participez à cette étude. Toutefois, en participant à cette 
étude vous nous aiderez à mieux comprendre les facteurs de risque responsables 
de certaines maladies cardiovasculaires. Il se peut que vous aidiez également les 
générations à venir en faisant avancer nos connaissances sur ces maladies et le 
traitement de personnes atteintes de maladies cardiovasculaires et des maladies 
associées. Si vous êtes d’accord, nous vous informerons périodiquement du progrès 
des recherches qui découleront de ce projet. 
5. Mes données personnelles seront-elles traitées confidentiellement? 
Données personnelles : Dans cette étude tous vos renseignements personnels tels 
que votre nom et votre adresse seront sauvegardés séparément (c’est à dire mis 
sous clé dans des endroits séparés) des données médicales, des données de 
laboratoire et des résultats de l’analyse génétique. Ces données seront codées par 
un numéro et pas par votre nom. Seuls le médecin de l’étude et le personnel 
directement rattaché à l’étude pourront associer votre numéro de sujet à votre nom. 
Vos données personnelles ne seront pas divulguées aux personnes qui analysent le 
matériel génétique. Confidentialité : Si vous être d’accord, nous informerons votre 
médecin traitant de votre participation à cette étude et nous lui ferons parvenir les 
valeurs de votre tension artérielle et les résultats des analyses de cholestérol, de 
triglycérides et de glucose sanguin. Nous demanderons également à votre médecin 
traitant de nous fournir les résultats de votre tension artérielle avant votre 
participation à cette étude. Votre nom ne figurera sur aucune publication ni aucun 
rapport sur cette étude. En acceptant de participer à ce projet, vous autorisez des 
personnes accréditées de vérifier le bon déroulement de l’étude et d’examiner des 
données médicales ou des résultats pouvant vous concerner. Ces personnes 
comprennent des membres de la Commission d’Ethique locale, les autorités locales, 
les personnes qui collaborent avec la compagnie pharmaceutique qui sponsorise 
le projet ou ses partenaires. Données génétiques:  Votre échantillon et vos 
informations médicales seront codés au moyen d’un numéro de participant et non 
par votre nom. Les chercheurs associés à cette étude à Lausanne, ainsi qu’à 
GlaxoSmithKline et ses partenaires auront accès à ce matériel et aux 
renseignements codés mais à aucun renseignement d’identification personnel tel 
que votre nom. Comme les échantillons auront été codés, il ne vous sera pas 
possible de connaître les résultats de l’analyse de votre ADN. Votre médecin traitant 
ne connaîtra pas non plus les résultats de l’analyse. 
Vos données médicales et tous les résultats seront saisis dans un ordinateur et 
entreposés dans une base de données électronique. Vos données et vos résultats 
médicaux pourront être envoyés à des chercheurs travaillant pour compagnie 
pharmaceutique partenaire du projet. Ces données codées seront sauvegardées et 
traitées selon les lois en vigueur pour protéger la confidentialité des personnes 
participant à des projets de recherche. 
3 
6. Qu’adviendra-t-il des informations médicales et des échantillons que je 
fournis ? 
En cédant aux investigateurs la possession des échantillons vous leur cédez aussi la 
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propriété de ces derniers. Vous conservez néanmoins le droit de déterminer le sort 
de ces échantillons qui ne seront pas l’objet d’autres utilisations que celles qui sont 
nécessaires aux fins de la présente étude. Le matériel génétique (ADN) sera prélevé 
des cellules contenues dans le sang que vous donnerez. Afin d’obtenir suffisamment 
d’ADN pour permettre une analyse complète, certaines cellules seront 
immortalisées, c’est à dire qu’elles seront cultivées et se multiplieront dans un 
laboratoire. Comme ces cellules continueront à croître, il y aura davantage de 
matériel génétique à étudier. De cette façon, vous n’aurez pas à retourner au site 
pour donner des échantillons de sang supplémentaires. 
Les échantillons et les données médicales seront envoyés aux Etats Unis ou en 
Grande-Bretagne pour les analyses génétiques nécessaires aux fins de la présente 
étude. Le matériel génétique, les échantillons de sang et les lignées cellulaires 
seront entreposées par la société de produits pharmaceutiques qui sponsorise cette 
étude. Les échantillons seront conservés pour une période de 50 ans à la suite de 
quoi ils seront détruits. 
7. Ma participation est-elle volontaire ? Que se passera-t-il si je ne veux plus 
participer à l’étude ? 
La participation à cette étude est entièrement volontaire. Vous pouvez décider d’y 
participer et vous retirer de l’étude à n’importe quel moment. Si vous décidez de 
vous retirer de cette étude, vous n’êtes pas tenu d’en fournir les raisons et aucune 
de ces décisions n’influencera les soins médicaux qui vous seront donnés par la 
suite. Au cas où vous vous retireriez de cette étude, tous les échantillons seront 
détruits y compris tout le matériel génétique et les lignées cellulaires. Toutefois, les 
chercheurs et leurs collaborateurs conserveront toutes les données médicales 
récoltées jusque-là, sauf si vous vous y opposez. Le cas échéant, votre autorisation 
sera sollicitée à ce moment-là. 
8. Puis-je être exclu(e) de cette étude ? 
Vous pourrez être exclu(e) de cette étude au cas où le personnel de l’étude 
déciderait que vous ne remplissez pas les critères d’inclusion. Dans certains cas 
particuliers, vos données médicales et vos échantillons pourront ne pas être utilisés 
et seront détruits. Ceci pourrait se produire si il y a un nombre insuffisant de 
participants ou si l’étude est interrompue pour d’autres raisons. 
9. Serais-je rémunéré(e) pour ma participation à cette étude ? 
Non, vous ne serez par rémunéré pour votre participation à cette étude mais vos 
frais de déplacement - selon le tarif des transports publics - pour vous rendre au 
centre de recrutement ou pour vous garer près du centre de recrutement seront 
couverts. 
4 
10. Est-ce que je bénéficierai financièrement de cette étude ? 
Vous ne bénéficierez pas financièrement de cette étude. En acceptant de participer 
à cette étude, vous donnez votre accord pour que les chercheurs rattachés à cette 
étude ainsi que leurs partenaires dans le secteur privé puissent utiliser les résultats 
et les documents de cette recherche, et tout développement ou invention issus de 
cette recherche à des fins commerciales et/ou de propriété intellectuelle. Il n’y a 
aucune intention de vous offrir, en tant que participant à la recherche, une 
compensation financière quelconque découlant des développements ou des 
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inventions issus de cette recherche. En signant ce formulaire vous acceptez que les 
chercheurs associés à cette étude, y compris des sociétés de produits 
pharmaceutiques et autres sociétés privées puissent faire des demandes de brevets 
sur la base des développement issus de cette recherche, étant précisé que ce ne 
seront pas les éléments biologiques prélevés sur vous qui seront comme tels objets 
de ces 
brevets. 
11. Quels sont les développements potentiels futurs de cette étude ? 
Cette étude devrait nous permettre d’avoir une bonne estimation de la fréquence des 
facteurs de risque cardiovasculaires dans la population de Lausanne actuellement. 
Mais les conséquences à l’avenir de ces facteurs de risque sur la santé représentent 
aussi un point important. Nous aimerions éventuellement, dans le cadre d’une 
nouvelle étude, pouvoir connaître comment se développe votre état de santé au 
cours de ces prochaines années. Si tel devait être le cas et si vous êtes d’accord, 
nous prendrions alors contact avec vous par écrit. Toute sollicitation pour un 
nouveau projet sera faite avec l’accord de la Commission d’éthique. 
Vous pouvez nous contacter si vous avez des questions sur cette étude, sur vos 
droits ou si vous désirez vous retirer de l’étude. 
Dr. Peter Vollenweider 
Département de Médecine Interne 
CHUV 
1001 Lausanne 
Tel: 021 314 09 46 
 
English Version (Google Translate). 
1 
Information Form for participants 
 
1. Reasons and objectives of the study Cardiovascular diseases such as myocardial 
infarction, stroke are among the most common diseases of our society and are an 
important cause mortality. Many factors can increase the risk of developing 
cardiovascular disease, including high blood pressure (hypertension), tobacco, 
diabetes, obesity, family history of cardiovascular disease and lack Exercise. While 
some of these risk factors depend on the lifestyle (tobacco, exercise, nutrition) others 
have a strong genetic component (hypertension, diabetes). To better understand the 
influence of risk factors and to discover new genes involved in cardiovascular 
disease, it is necessary to study populations large and homogeneous. The objectives 
of this study are: 
a) Undertake a survey of cardiovascular risk factors in the broad sense of 
homogeneous population as Lausanne, 
b) To study the genetic material (DNA) and markers (proteins and fats, as 
cholesterol) associated with cardiovascular risk factors at large and related diseases 
such as hypertension, diabetes, obesity and disorders mood. 
We hope to recruit 6,000 participants in Lausanne. 
The study will be conducted by researchers at the Centre Hospitalier Universitaire 
Vaudois (CHUV) and the University of Lausanne in association with GlaxoSmithKline 
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(GSK). 
2. What should I do if I agree to take part in this study? If you agree to participate in 
this study, we will complete a questionnaire about your medical history, medical 
history of your family, your state current health and your current treatment and your 
ethnicity. We will measure your weight, height, and blood pressure. We ask you to 
give 50 ml sample of fasting blood and a urine sample of 10 ml. Equipment genetic 
(DNA) will be extracted from your blood and markers will be measured in your blood 
and urine. 
Finally, we will ask you if you agree that we contact you in the future to answer some 
questions about your health and tension blood. 
3. What are the risks? 
Physical risks and discomfort associated with the blood test are the same as for any 
blood sample and may include hematoma or local inflammation. 
2 
4. What are the advantages for me? 
We will measure your blood pressure, cholesterol, and triglyceride glucose (sugar) in 
the blood and the doctor responsible for the study will contact you Results of these 
analyzes. There will be no immediate benefit to you if you participate in this study. 
However, in this study will help us better understand the risk factors responsible for 
cardiovascular diseases. You may also help future generations by advancing our 
knowledge about these diseases and treating people with diseases cardiovascular 
and related diseases. 
If you agree, we will inform you periodically of the progress of research that will result 
from this project. 
5. My personal data be treated confidentially? 
Personal data: In this study all your personal information such as your name and 
address will be saved separately (ie locked up in separate locations) medical data, 
laboratory data and results genetic analysis. These data will be encoded by a 
number and not by name. 
Only the study doctor and staff directly attached to the study can associate your 
subject number in your name. Your personal data will not be disclosed to those that 
analyze the genetic material. 
Privacy: If you agree, we will inform your doctor of your Participation in this study and 
we will send him the values of your blood pressure and the results of analysis of 
cholesterol, triglycerides, blood glucose. We also ask your doctor to provide us with 
the results of your blood pressure before participating in this study. Your name will 
not appear on any publication nor any report on this study. By agreeing to participate 
in this project, you allow accredited persons to verify the success of the study and 
examine medical data or results that may concern you. These people include 
members of the local Ethics Committee, the authorities local, people who collaborate 
with the pharmaceutical company sponsoring the project or its partners. 
genetic data: 
Your sample and your medical information will be coded by a number of participant 
and not by name. The researchers involved in this study in Lausanne, as well at 
GlaxoSmithKline and its partners will have access to this material and information 
coded but no personal identification information such as your name. As samples 
  35 
have been encoded, it will not be possible to know the results of analyzing your 
DNA. Your doctor does not know the results of analysis. 
Your medical data and all results are entered into a computer and stored in an 
electronic database. Your data and your medical results will be sent to researchers 
working for pharmaceutical company partner project. These coded data will be 
stored and processed according to the laws in force protecting the privacy of 
individuals participating in research projects. 
3 
6. What will it medical information and samples I provided? 
By yielding to the investigators possession of the samples you have transferred them 
also property thereof. You still retain the right to determine the fate of these Samples 
that will not be subject to other uses than those required for the purposes of this 
study. The genetic material (DNA) will be charged cells contained in the blood you 
give. In order to obtain sufficient DNA for enable a complete analysis, some cells will 
be immortalized, ie they will be grown and multiply in a laboratory. As these cells 
continue to grow, there will be more genetic material to study. Like this, you will not 
have to return to the site to give blood samples additionally. 
The samples and medical data will be sent to the United States or in Great Brittain 
for DNA analysis necessary for this study. The genetic material, blood samples and 
cell lines will be stored by the pharmaceutical company sponsoring the study. The 
samples will be retained for a period of 50 years after which they will be destroyed. 
7. My participation is voluntary it? What will happen if I do not want participate in the 
study? Participation in this study is entirely voluntary. You can decide to participate 
and withdraw from the study at any time. If you decide from this study, you are not 
required to provide reasons and none of these decisions influence the medical care 
that will be given later. In case you would withdraw you from this study, all samples 
will be destroyed including all genetic material and cell lines. However, researchers 
and 
Contributors retain all medical data collected so far, unless you you oppose it. If 
necessary, your permission will be sought at that time. 
8. Can I be excluded (e) of this study? 
You can be excluded (e) of this study if the study staff decide that you do not meet 
the inclusion criteria. In special cases, your medical data and samples will not be 
used and will be destroyed. This could occur if there is an insufficient number of 
participants or if the study is interrupted for other reasons. 
9. Will I be paid (e) for my participation in this study? 
No, you will not be paid for by your participation in this study but your costs 
movement - depending on the price of public transport - to get to the center of 
recruitment or to park near the recruitment center will be covered. 
4 
10. Do I will receive financially from this study? 
You do not financially benefit from this study. By agreeing to participate in this study, 
you consent to the researchers from this study and their partners in the private 
sector to use the results and documents This research and development or any 
invention resulting from this research purposes commercial and / or intellectual 
property. There is no intention to offer in 
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As a research participant, any financial compensation arising developments or 
inventions resulting from this research. By signing this form you agree that 
researchers involved in this study, including companies pharmaceuticals and other 
private companies can make requests patents on the basis of development from this 
research, given that it will not be the biological elements taken you to be such 
objects as these patents. 
11. What are the potential future developments of this study? 
This study should allow us to have a good estimate of the frequency of 
cardiovascular risk factors in the population of Lausanne today. But the 
consequences for the future of these health risk factors also represent a important 
point. We would possibly as part of a new study, 
to know how to develop your health over the next years. If that were the case and if 
you agree, we would then Contact you in writing. Any request for a new project will 
be made with the agreement of the Ethics Commission. 
 
You can contact us if you have questions about this study or your rights 
if you wish to withdraw from the study. 
 
Dr. Peter Vollenweider 
Department of Internal Medicine 
CHUV 
1001 Lausanne 
Tel: 021 314 September 46 
 
6.3 Uppsala Fibromyalgia study 
a) Ethical Approval for the study 
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b) Informed consent form 
Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj Napoca  
Sef Lucr. Dr Constantin Bodolea  
 
Foaie de Consimtamant Informat  
 
Acord de donare si utilizare in scop stiintific a unei  probe biologice de lichid 
cefalorahidian si singe. 
 
Stimate Doamna, Stimat Domn, 
Prin prezentul document informativ va solicitam acordul pentru donarea unor 
esantioane de lichid cefalorahidian (1-3 mL) si singe (5 mL) in scopul depistarii unor 
posibile complicatii postoperatorii, amelioarea tratamentului postoperator al 
dumneavostra si al altor pacienti.  
 
Scopul recoltarii probelor biologice: 
Scopul nostru este de a depista existenta unor compusi care circula in singe sau 
lichidul cefalorahidian si a caror aparitie ar putea fi corelata cu dezvoltarea unor 
complicatii postoperatorii. Cunoasterea acestor substante ar putea ajuta la 
depistarea rapida si tratamentul complicatiilor. Probele recoltate vor fi analizate in 
laboratoare foarte performante din Romania sau Suedia. 
In cazul in care Dumneavoastra decideti participarea la acest studiu, trebuie sa 
stiti si sa fiti de acord cu urmatoarele: 
- Se vor recolta 5 ml de singe venos prin punctia unei vene periferice. 
- Odata cu punctia rahidiana (“in coloana”) prin care se injecteaza 
anestezicul local pentru anestezia subarahnoidiana (anestezia asa zis “in 
coloana”), se vor recolta maxim 3 mL de lichid cefalorahidian.  
- Dorim sa va asiguram ca acest volum de lichid cefalorahidian extras este 
foarte mic si nu exista nici un risc de complicatii prin extragerea lui. 
- Participarea la studiu NU va modifica in nici un mod tratamentul care 
oricum v-ar fi fost acordat (tipul de anestezie, operatie sau tratament 
postoperator). Refuzul de a dona aceste esantioane de lichid 
cefalorahidian sau singe NU va modifica in nici un fel tratamentul 
Dumneavoastra. 
- De asemenea, donarea acestor probe nu este insotita de vreun 
beneficiu financiar. 
- Identitatea Dvs. NU va fi divulgata, probei de singe si de lichid 
cefalorahidian le va fi acordat un Cod de inregistrare. Singele si lichidul 
cefalorahidian vor fi depozitate in congelatoare speciale, insemnate cu 
etichete cu numar si fara datele Dvs personale (nume, adresa, etc). 
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Singura persoana detinatoare a datelor Dvs de identitate este Direcorul de 
proiect din partea Universitatii de Medicina si Farmacie Cluj-Napoca Dr. 
Constantin Bodolea. 
- Consimtamintul Dvs. va fi obtinut atit verbal cit si in scris prin 
semnatura de acord, pe acest formular de accept al donarii probelor 
biologice. 
 
Protocol de recoltare si investigatie. 
I.In ziua dinaintea sau in cea a operatiei odata cu obtinerea acceptului de participare, 
se vor culege urmatoarele date : 
1.Datele demografice: virsta, greutatea, inaltimea, sexul  
2.Probele de laborator uzuale 
3.Bolile  asociate, terapia curenta, istoricul consumului de alcool si/sau alte droguri, 
fumat.(vezi Anexa I) 
4.Clasa de risc anestezic ASA (American Society of Anaesthesiologists) 
5.Existenta unor tipuri anume de durere acuta sau cronica 
 
II.Preoperator se vor recolta 5 ml singe pentru examinari de laborator specifice 
(biomarkeri). 
III.Punctia subarahnoidiana va fi realizata dupa tehnica standard. (vezi anexa II) 
III. Vor fi inclusi in cercetare numai pacientii care vor fi operati in anestezie 
subarahnoidiana, socotita ca fiind cea mai potrivita interventiei chirurgicale propuse 
si care accepta donarea a 3 mL de lichid cefalorahidian. 
IV. Se vor inregistra complicatiile postoperatorii si consumul de analgezice in primele 





Sunt de acord sa particip la cercetare, 
 
 
Semnatura pacientului    Semnatura medicului instructor 
 
English Translation (Google Translate) 
 
University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj Napoca 
Lecturer. Dr Constantin Bodola 
 
Informed Consent sheet 
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Agreement for scientific donation and use of biological samples of cerebrospinal fluid 
and blood. 
 
Dear Ladies and Gentlemen, 
We hereby consent to donation information we request some samples of 
cerebrospinal fluid (1-3 mL) and blood (5 mL) in order to detect possible 
postoperative complications, postoperative treatment of relief of your and other 
patients. 
 
The purpose of harvesting biological samples: 
Our goal is to recognize the existence of compounds that circulate in the blood or 
cerebrospinal fluid and whose appearance could be correlated with the development 
of postoperative complications. Knowledge of these substances could help early 
detection and treatment of complications. Samples will be analyzed in laboratories in 
Romania or Sweden high performance. 
You decide if participating in this study, you must know and agree to the following: 
- It will yield 5 ml of venous blood through a vein puncture. 
- With spinal puncture ( "column") which injects local anesthetic for subarachnoid 
anesthesia (anesthesia so-called "column"), will be collected within 3 mL 
cerebrospinal fluid. 
- We want to assure you that this volume of cerebrospinal fluid extracted is very 
small and there is no risk of complications by extracting it. 
- Participation in the study will not alter in any way the treatment anyway would have 
been granted (type of anesthesia, surgery or postoperative treatment). Refusing to 
donate these samples of cerebrospinal fluid or blood will not change in any way your 
treatment. 
- The donation of these samples is not accompanied by any financial benefit. 
- Your identity will not be shared, sample blood and cerebrospinal fluid will be given 
a registration code. Blood and spinal fluid will be stored in special freezers, marked 
with numbered tags without your personal data (name, address, etc). The only 
person holding your identity data is Direcorul project from the University of Medicine 
and Pharmacy Cluj-Napoca Dr. Constantin Bodola. 
- Your Consent will be achieved both verbal as well as written by the signature of 
agreement on this form accept the donation of biological samples. 
 
Protocol for cleaning and investigation. 
I.In or the day before surgery with getting agreeing to participate, will collect the 
following data: 
1. demographic: age, weight, height, sex 
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2. usual laboratory 
3. associated current therapy, history of alcohol and / or other drugs, smoking. (See 
Annex I) 
4. anesthetic risk ASA (American Society of Anaesthesiologists) 
5. specific kinds of acute or chronic pain 
 
II. Pre-operator 5 ml blood will be collected for specific laboratory exams 
(biomarkers). 
III.Punctia subarachnoid will be conducted by standard technique. (See Annex II) 
III. They will participate in research only patients who will have surgery in 
subarachnoid anesthesia, reckoned as the most appropriate surgery and accepting 
the proposed donation of 3 mL of cerebrospinal fluid. 
IV. Will be recorded postoperative complications and analgesic consumption in the 





I agree to participate in research 
 
Signature doctor, patient, instructor 
